ASTRAZEN - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.1
| Stock Code | ASTRAZEN | Market Cap | 20,896 Cr. | Current Price | 8,370 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 100 | Book Value | 320 ₹ | Dividend Yield | 0.38 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,693 ₹ | DMA 200 | 8,660 ₹ |
| Chg in FII Hold | -0.03 % | Chg in DII Hold | 0.29 % | PAT Qtr | 31.6 Cr. | PAT Prev Qtr | 58.1 Cr. |
| RSI | 36.9 | MACD | -82.7 | Volume | 3,355 | Avg Vol 1Wk | 5,632 |
| Low price | 6,502 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.32 | Debt to equity | 0.04 |
| 52w Index | 44.6 % | Qtr Profit Var | -42.3 % | EPS | 80.4 ₹ | Industry PE | 27.2 |
📊 Analysis: ASTRAZEN currently trades at ₹8,370, below both 50 DMA (₹8,693) and 200 DMA (₹8,660). RSI at 36.9 indicates oversold conditions, but MACD (-82.7) remains negative, showing weak momentum. Intraday volume (3,355) is lower than the weekly average (5,632), suggesting limited trader participation. The stock is not an ideal candidate for intraday trading today.
💡 Optimal Buy Price: ₹8,300–₹8,350 if volume improves and momentum indicators turn positive.
🎯 Profit Exit Levels: ₹8,500 (short-term resistance), ₹8,650 (near DMA levels).
🛡️ Stop-Loss: ₹8,200 to limit downside risk.
⏱️ If Already Holding: Exit near ₹8,500 if momentum fails to strengthen. If price breaks below ₹8,200 with volume, exit immediately to avoid deeper losses.
Positive
- Strong ROCE (33.4%) and ROE (23.6%) reflect efficient capital use.
- Low debt-to-equity ratio (0.04) ensures financial stability.
- DII holdings increased (+0.29%), showing domestic institutional support.
Limitation
- High P/E ratio (100) compared to industry PE (27.2) indicates stretched valuation.
- Quarterly profit dropped sharply (-42.3%), raising earnings concerns.
- Weak intraday volume compared to average, limiting trading opportunities.
Company Negative News
- PAT fell from ₹58.1 Cr. to ₹31.6 Cr., showing earnings pressure.
- FII holdings decreased (-0.03%), signaling reduced foreign investor confidence.
Company Positive News
- Strong long-term fundamentals with consistent ROCE and ROE.
- Stable dividend yield (0.38%) despite earnings volatility.
Industry
- Pharma sector remains defensive with steady demand.
- Industry PE at 27.2 highlights sector stability compared to ASTRAZEN’s premium valuation.
Conclusion
⚠️ ASTRAZEN is not a strong intraday candidate today due to weak momentum, low volume, and stretched valuations. Traders should only consider entry if volume spikes and price sustains above ₹8,350. Otherwise, risk of downside remains high. Long-term investors may still find value given strong fundamentals, but intraday traders should remain cautious.